Barbara Friedland is an associate in the Population Council’s HIV and AIDS program. Friedland has been involved in both clinical and behavioral research, primarily focused on HIV prevention. She has also coordinated several international clinical trials of the Council’s first candidate microbicide, Carraguard®, and is currently managing the first in-human study of the Council’s ARV-based microbicide, PC-1005 (MIV-150 and zinc acetate in a carrageenan gel).
This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the IMPT, CAMI Health, PHI, and its partners and do not necessarily reflect the views of USAID or the U.S. Government.